Stratos Investment Management LLC Acquires 32,559 Shares of Novo Nordisk A/S (NYSE:NVO)

Stratos Investment Management LLC increased its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 63.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 84,046 shares of the company's stock after buying an additional 32,559 shares during the quarter. Stratos Investment Management LLC's holdings in Novo Nordisk A/S were worth $5,836,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Strategic Investment Solutions Inc. IL lifted its stake in shares of Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after acquiring an additional 300 shares during the last quarter. Park Square Financial Group LLC bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at about $29,000. Transce3nd LLC bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at about $33,000. North Capital Inc. bought a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at about $27,000. Finally, Copeland Capital Management LLC lifted its stake in shares of Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after acquiring an additional 255 shares during the last quarter. Institutional investors own 11.54% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on NVO shares. Wall Street Zen raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. BMO Capital Markets reiterated a "market perform" rating and issued a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Guggenheim cut Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Finally, Dbs Bank cut Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S presently has an average rating of "Hold" and a consensus price target of $112.00.

Novo Nordisk A/S Stock Up 0.4%

Shares of NVO traded up $0.31 on Tuesday, reaching $69.63. The stock had a trading volume of 9,838,730 shares, compared to its average volume of 7,271,482. The firm has a market capitalization of $310.90 billion, a price-to-earnings ratio of 20.60, a price-to-earnings-growth ratio of 1.35 and a beta of 0.64. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74. The company has a 50-day simple moving average of $70.10 and a 200-day simple moving average of $75.41. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $143.69.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting analysts' consensus estimates of $0.92. The company had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. Sell-side analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.